Korean Drug Co., Ltd. (KOSDAQ:014570)

Korean Drug Statistics

Total Valuation

Korean Drug has a market cap or net worth of KRW 43.16 billion. The enterprise value is 13.22 billion.

Market Cap	43.16B
Enterprise Value	13.22B

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	Dec 29, 2025

Share Statistics

Korean Drug has 10.91 million shares outstanding.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	50.60%
Owned by Institutions (%)	n/a
Float	5.39M

Valuation Ratios

The trailing PE ratio is 6.63.

PE Ratio	6.63
Forward PE	n/a
PS Ratio	0.69
PB Ratio	0.52
P/TBV Ratio	0.52
P/FCF Ratio	3.41
P/OCF Ratio	3.29
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.49, with an EV/FCF ratio of 1.04.

EV / Earnings	2.03
EV / Sales	0.21
EV / EBITDA	1.49
EV / EBIT	1.91
EV / FCF	1.04

Financial Position

The company has a current ratio of 8.33, with a Debt / Equity ratio of 0.00.

Current Ratio	8.33
Quick Ratio	6.41
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.00
Interest Coverage	1,780.37

Financial Efficiency

Return on equity (ROE) is 8.08% and return on invested capital (ROIC) is 10.98%.

Return on Equity (ROE)	8.08%
Return on Assets (ROA)	4.72%
Return on Invested Capital (ROIC)	10.98%
Return on Capital Employed (ROCE)	8.04%
Weighted Average Cost of Capital (WACC)	5.83%
Revenue Per Employee	231.51M
Profits Per Employee	24.12M
Employee Count	270
Asset Turnover	0.68
Inventory Turnover	2.01

Taxes

In the past 12 months, Korean Drug has paid 1.29 billion in taxes.

Income Tax	1.29B
Effective Tax Rate	16.49%

Stock Price Statistics

The stock price has decreased by -12.50% in the last 52 weeks. The beta is 0.29, so Korean Drug's price volatility has been lower than the market average.

Beta (5Y)	0.29
52-Week Price Change	-12.50%
50-Day Moving Average	4,039.00
200-Day Moving Average	4,405.73
Relative Strength Index (RSI)	47.15
Average Volume (20 Days)	14,998

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Korean Drug had revenue of KRW 62.51 billion and earned 6.51 billion in profits.

Revenue	62.51B
Gross Profit	26.60B
Operating Income	6.91B
Pretax Income	7.80B
Net Income	6.51B
EBITDA	8.88B
EBIT	6.91B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 30.00 billion in cash and 57.84 million in debt, with a net cash position of 29.94 billion or 2,743.63 per share.

Cash & Cash Equivalents	30.00B
Total Debt	57.84M
Net Cash	29.94B
Net Cash Per Share	2,743.63
Equity (Book Value)	83.07B
Book Value Per Share	n/a
Working Capital	60.77B

Cash Flow

In the last 12 months, operating cash flow was 13.11 billion and capital expenditures -457.00 million, giving a free cash flow of 12.65 billion.

Operating Cash Flow	13.11B
Capital Expenditures	-457.00M
Depreciation & Amortization	1.97B
Net Borrowing	-84.21M
Free Cash Flow	12.65B
FCF Per Share	1,159.55

Margins

Gross margin is 42.55%, with operating and profit margins of 11.06% and 10.42%.

Gross Margin	42.55%
Operating Margin	11.06%
Pretax Margin	12.47%
Profit Margin	10.42%
EBITDA Margin	14.21%
EBIT Margin	11.06%
FCF Margin	20.24%

Dividends & Yields

This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 4.02%.

Dividend Per Share	160.00
Dividend Yield	4.02%
Dividend Growth (YoY)	12.50%
Years of Dividend Growth	2
Payout Ratio	26.57%
Buyback Yield	n/a
Shareholder Yield	4.02%
Earnings Yield	15.09%
FCF Yield	29.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Korean Drug has an Altman Z-Score of 5.51 and a Piotroski F-Score of 4.

Altman Z-Score	5.51
Piotroski F-Score	4